Joshua Brody

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Joshua Brody
Apr 24, 2025, 12:10 | Science
Joshua Brody: Quick summary on using CRISPR to edit T-cells
Joshua Brody, Director of Lymphoma Immunotherapy Program and Associate Professor of Division of Hematology and…
Apr 23, 2025, 17:13 | Science
Joshua Brody Highlights Consensus Statement on Richter Syndrome in Blood Journal
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared an…
Apr 22, 2025, 13:49 | Science
Joshua Brody: How to measure T-cell bystander tumor killing to prevent antigen escape after cancer immunotherapy
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared an article…
Apr 16, 2025, 09:11 | Blog
Joshua Brody: Mobilizing dendritic cells to teach T cells to recognize and kill tumors
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared a…
Apr 15, 2025, 13:28 | Blog
Joshua Brody: Combining lymphoma immunotherapy with standard of care
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai,…
Apr 4, 2025, 08:42 | Insight
Joshua Brody: Which steroid is right for CRS?
Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at…
Mar 5, 2025, 07:53 | Blog
A major breakthrough in treating diffuse large B-cell lymphoma - Mount Sinai Department of Medicine
Mount Sinai Department of Medicine shared a post on LinkedIn: "An international team led by Joshua Brody,…
Jan 7, 2025, 14:30 | Dialogues
ASCO24 Updates: Joshua Brody on Epcoritamab Immunotherapy for DLBCL
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Dec 24, 2024, 11:40 | Blog
Joshua Brody: Practice-changing ASH24 updates on Follicular Lymphoma Immunotherapy
Joshua Brody, Director of Lymphoma Immunotherapy Program at The Icahn School of Medicine at Mount…
Nov 29, 2024, 20:13 | Insight
Joshua Brody: Bispecific antibody immunotherapy for lymphoma
Joshua Brody, Director of Lymphoma Immunotherapy Program at The Icahn School of Medicine at Mount…
Oct 13, 2024, 08:06 | Career
Joshua Brody: Great job opportunity for anyone with PharmD
Joshua Brody, Director, Lymphoma Immunotherapy Program, The Icahn School of Medicine at Mount Sinai, shared…
Sep 12, 2024, 09:29 | Blog
Joshua Brody: How to get access to promising new immunotherapy treatments or patients with follicular lymphoma?
Joshua Brody, Director, Lymphoma Immunotherapy Program, The Icahn School of Medicine at Mount Sinai shared a…
Sep 5, 2024, 05:09 | Blog
Joshua Brody: Excited for the CME event on CAR T-cell therapy for lymphoma and CLL at SOHO2024
Joshua Brody shared on LinkedIn: "Excited for the Amps-to-go-up-to-11 at tomorrow's CME event on CAR…
Aug 20, 2024, 05:20 | Dialogues
Low-Grade Lymphomas: Dr. Joshua Brody on Treatments, Strategies, and Innovations
In this episode of OncoDaily interviews, Dr. Joshua Brody, director of the lymphoma immunotherapy program…
Aug 14, 2024, 10:54 | Blog
Joshua Brody: Great Podcast about Bispecific Antibody immunotherapy for aggressive and indolent lymphomas
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared on…
Aug 9, 2024, 10:21 | Insight
Immunotherapy with chemo improves survival for aggressive relapsed lymphoma
Joshua Brody, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at…
Jul 18, 2024, 00:18 | Insight
Joshua Brody: Impressive potency of chemo-free immunotherapy as 1st-line treatment for lymphoma
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared on…
All: 17 Posts: 1 - 100
Special Coverage